Replicel Life Sciences Inc
XTSX:RP

Watchlist Manager
Replicel Life Sciences Inc Logo
Replicel Life Sciences Inc
XTSX:RP
Watchlist
Price: 0.01 CAD Market Closed
Market Cap: 636.6k CAD
Have any thoughts about
Replicel Life Sciences Inc?
Write Note

Replicel Life Sciences Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Replicel Life Sciences Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Replicel Life Sciences Inc
XTSX:RP
Cash from Financing Activities
CA$1.9m
CAGR 3-Years
24%
CAGR 5-Years
11%
CAGR 10-Years
6%
Abcellera Biologics Inc
NASDAQ:ABCL
Cash from Financing Activities
$10.4m
CAGR 3-Years
-75%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Arch Biopartners Inc
XTSX:ARCH
Cash from Financing Activities
CA$1.4m
CAGR 3-Years
-23%
CAGR 5-Years
-3%
CAGR 10-Years
12%
Innovotech Inc
XTSX:IOT
Cash from Financing Activities
CA$104.7k
CAGR 3-Years
-26%
CAGR 5-Years
1%
CAGR 10-Years
0%
No Stocks Found

Replicel Life Sciences Inc
Glance View

Market Cap
614.3k CAD
Industry
Life Sciences Tools & Services

RepliCel Life Sciences, Inc. is a regenerative medicine company, which engages in the development of autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopeci, and skin aging. The company is headquartered in Vancouver, British Columbia and currently employs 1 full-time employees. The company went IPO on 2012-09-29. The company is focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia, and skin aging. Its product pipeline includes RCT-01 for Tendon Repair, RCS-01 for Skin Rejuvenation, RCH-01 Hair Growth and RCI-02 Dermal Injector Publication . RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle for the treatment of chronic Achilles tendinopathy. RCS-01 is an autologous cell therapy being developed to rejuvenate aging or Ultraviolet (UV)-damaged skin. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to deliver a variety of injectable substances in and under the skin with a range of needle configurations.

RP Intrinsic Value
0.04 CAD
Undervaluation 77%
Intrinsic Value
Price

See Also

What is Replicel Life Sciences Inc's Cash from Financing Activities?
Cash from Financing Activities
1.9m CAD

Based on the financial report for Sep 30, 2023, Replicel Life Sciences Inc's Cash from Financing Activities amounts to 1.9m CAD.

What is Replicel Life Sciences Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
6%

Over the last year, the Cash from Financing Activities growth was 32%. The average annual Cash from Financing Activities growth rates for Replicel Life Sciences Inc have been 24% over the past three years , 11% over the past five years , and 6% over the past ten years .

Back to Top